Stock listing
Obi Pharma, Inc.
Selected listing: 4174 · TPEX · TWD · TW
Obi Pharma, Inc. (TPEx:4174), Health Technology. Latest release Jan 12, 2026: OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement…
- Ticker
- TPEx:4174
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- TPEx
- Currency
- TWD
About Obi Pharma, Inc.
Obi Pharma, Inc. (4174) is listed on 6ix with investor news, events, company updates, and market data in one place. Follow the company page to track new releases, upcoming presentations, and the latest information available on 6ix.
Latest news from Obi Pharma, Inc.
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
January 12, 2026
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors
September 2, 2025
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
June 6, 2025
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC
April 30, 2025
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science
April 22, 2025